Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1

Conditions

Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × AZD4547 × Clear all
NCT01824901 2023-06-29

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Completed
2 enrolled 4 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01791985 2022-08-22

RADICAL

Imperial College London

Phase 1/2 Completed
52 enrolled 17 charts
Breast

Breast Neoplasms

NCT01202591 2016-02-11

GLOW

AstraZeneca

Phase 1/2 Completed
127 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡